Virax Biolabs Group Ltd (VRAX) — Institutional Holders, Q2 2026
2 institutional investment managers reported a VRAX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $77.6K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
VRAX in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- JANE STREET GROUPNew · +26,385 sh+$79.2K
- UBS Group AGNew · +4 sh+$12.00
Biggest sellers
- ARMISTICE CAPITALSold out · -35,152 sh-$105.5K
- Jump FinancialSold out · -1,629 sh-$4.9K
- OSAICSold out · -1 sh-$3.00
- Farther Finance AdvisorsSold out · -1 sh-$3.00
VRAX 13F holders ranked 1–2 of 2
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | JANE STREET GROUP#1 · 26,385 sh | 26,385 | $77.6K | 0.00% | New |
| 2 | UBS Group AG#2 · 4 sh | 4 | $12.00 | 0.00% | New |
Funds that sold out of VRAX in Q2 2026 (4)
Held VRAX at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| ARMISTICE CAPITAL35,152 sh | 35,152 | $193.2K |
| Jump Financial1,629 sh | 1,629 | $9.0K |
| OSAIC1 sh | 1 | $4.00 |
| Farther Finance Advisors1 sh | 1 | $4.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.